Please use a PC Browser to access Register-Tadawul
Get It
Cytosorbents shares are trading lower after the company announced an analysis by the independent DSMB on the STAR-T trial showed the study did not meet the primary effectiveness endpoint in the overall patient population.
CytoSorbents Corporation CTSO | 1.14 | +2.70% |